@article{LisowskiHartrampfHasenaueretal.2023, author = {Lisowski, Dominik and Hartrampf, Philipp E. and Hasenauer, Natalie and Nickl, Vera and Monoranu, Camelia-Maria and Tamihardja, J{\"o}rg}, title = {Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report}, series = {BMC Neurology}, volume = {23}, journal = {BMC Neurology}, doi = {10.1186/s12883-023-03450-w}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357996}, year = {2023}, abstract = {Background Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment. Conclusions E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.}, language = {en} } @article{LisowskiLutyjAbazarietal.2023, author = {Lisowski, Dominik and Lutyj, Paul and Abazari, Arya and Weick, Stefan and Traub, Jan and Polat, B{\"u}lent and Flentje, Michael and Kraft, Johannes}, title = {Impact of Radiotherapy on Malfunctions and Battery Life of Cardiac Implantable Electronic Devices in Cancer Patients}, series = {Cancers}, volume = {15}, journal = {Cancers}, number = {19}, issn = {2072-6694}, doi = {10.3390/cancers15194830}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-358008}, year = {2023}, abstract = {Purpose: This study analyses a large number of cancer patients with CIEDs for device malfunction and premature battery depletion by device interrogation after each radiotherapy fraction and compares different guidelines in regard to patient safety. Methods: From 2007 to 2022, a cohort of 255 patients was analyzed for CIED malfunctions via immediate device interrogation after every RT fraction. Results: Out of 324 series of radiotherapy treatments, with a total number of 5742 CIED interrogations, nine device malfunctions (2.8\%) occurred. Switching into back-up/safety mode and software errors occurred four times each. Once, automatic read-out could not be performed. The median prescribed cumulative dose at planning target volume (PTV) associated with CIED malfunction was 45.0 Gy (IQR 36.0-64.0 Gy), with a median dose per fraction of 2.31 Gy (IQR 2.0-3.0 Gy). The median maximum dose at the CIED at time of malfunction was 0.3 Gy (IQR 0.0-1.3 Gy). No correlation between CIED malfunction and maximum photon energy (p = 0.07), maximum dose at the CIED (p = 0.59) nor treatment localization (p = 0.41) could be detected. After excluding the nine malfunctions, premature battery depletion was only observed three times (1.2\%). Depending on the national guidelines, 1-9 CIED malfunctions in this study would have been detected on the day of occurrence and in none of the cases would patient safety have been compromised. Conclusion: Radiation-induced malfunctions of CIEDs and premature battery depletion are rare. If recommendations of national safety guidelines are followed, only a portion of the malfunctions would be detected directly after occurrence. Nevertheless, patient safety would not be compromised.}, language = {en} } @article{DietzschBraesigkSeideletal.2022, author = {Dietzsch, Stefan and Braesigk, Annett and Seidel, Clemens and Remmele, Julia and Kitzing, Ralf and Schlender, Tina and Mynarek, Martin and Geismar, Dirk and Jablonska, Karolina and Schwarz, Rudolf and Pazos, Montserrat and Weber, Damien C. and Frick, Silke and Gurtner, Kristin and Matuschek, Christiane and Harrabi, Semi Ben and Gl{\"u}ck, Albrecht and Lewitzki, Victor and Dieckmann, Karin and Benesch, Martin and Gerber, Nicolas U. and Obrecht, Denise and Rutkowski, Stefan and Timmermann, Beate and Kortmann, Rolf-Dieter}, title = {Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma—an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial}, series = {Strahlentherapie und Onkologie}, volume = {198}, journal = {Strahlentherapie und Onkologie}, number = {3}, issn = {0179-7158}, doi = {10.1007/s00066-021-01822-0}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-307812}, pages = {282-290}, year = {2022}, abstract = {Purpose In Germany, Austria, and Switzerland, pretreatment radiotherapy quality control (RT-QC) for tumor bed boost (TB) in non-metastatic medulloblastoma (MB) was not mandatory but was recommended for patients enrolled in the SIOP PNET5 MB trial between 2014 and 2018. This individual case review (ICR) analysis aimed to evaluate types of deviations in the initial plan proposals and develop uniform review criteria for TB boost. Patients and methods A total of 78 patients were registered in this trial, of whom a subgroup of 65 patients were available for evaluation of the TB treatment plans. Dose uniformity was evaluated according to the definitions of the protocol. Additional RT-QC criteria for standardized review of target contours were elaborated and data evaluated accordingly. Results Of 65 initial TB plan proposals, 27 (41.5\%) revealed deviations of target volume delineation. Deviations according to the dose uniformity criteria were present in 14 (21.5\%) TB plans. In 25 (38.5\%) cases a modification of the RT plan was recommended. Rejection of the TB plans was rather related to unacceptable target volume delineation than to insufficient dose uniformity. Conclusion In this analysis of pretreatment RT-QC, protocol deviations were present in a high proportion of initial TB plan proposals. These findings emphasize the importance of pretreatment RT-QC in clinical trials for MB. Based on these data, a proposal for RT-QC criteria for tumor bed boost in non-metastatic MB was developed.}, language = {en} } @article{AndratschkeAlheidAllgaeueretal.2018, author = {Andratschke, N. and Alheid, H. and Allg{\"a}uer, M. and Becker, G. and Blanck, O. and Boda-Heggemann, J. and Brunner, T. and Duma, M. and Gerum, S. and Guckenberger, M. and Hildebrandt, G. and Klement, R. J. and Lewitzki, V. and Ostheimer, C. and Papachristofilou, A. and Petersen, C. and Schneider, T. and Semrau, R. and Wachter, S. and Habermehl, D.}, title = {The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases}, series = {BMC Cancer}, volume = {18}, journal = {BMC Cancer}, doi = {10.1186/s12885-018-4191-2}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-221116}, year = {2018}, abstract = {Background The intent of this pooled analysis as part of the German society for radiation oncology (DEGRO) stereotactic body radiotherapy (SBRT) initiative was to analyze the patterns of care of SBRT for liver oligometastases and to derive factors influencing treated metastases control and overall survival in a large patient cohort. Methods From 17 German and Swiss centers, data on all patients treated for liver oligometastases with SBRT since its introduction in 1997 has been collected and entered into a centralized database. In addition to patient and tumor characteristics, data on immobilization, image guidance and motion management as well as dose prescription and fractionation has been gathered. Besides dose response and survival statistics, time trends of the aforementioned variables have been investigated. Results In total, 474 patients with 623 liver oligometastases (median 1 lesion/patient; range 1-4) have been collected from 1997 until 2015. Predominant histologies were colorectal cancer (n = 213 pts.; 300 lesions) and breast cancer (n = 57; 81 lesions). All centers employed an SBRT specific setup. Initially, stereotactic coordinates and CT simulation were used for treatment set-up (55\%), but eventually were replaced by CBCT guidance (28\%) or more recently robotic tracking (17\%). High variance in fraction (fx) number (median 1 fx; range 1-13) and dose per fraction (median: 18.5 Gy; range 3-37.5 Gy) was observed, although median BED remained consistently high after an initial learning curve. Median follow-up time was 15 months; median overall survival after SBRT was 24 months. One- and 2-year treated metastases control rate of treated lesions was 77\% and 64\%; if maximum isocenter biological equivalent dose (BED) was greater than 150 Gy EQD2Gy, it increased to 83\% and 70\%, respectively. Besides radiation dose colorectal and breast histology and motion management methods were associated with improved treated metastases control. Conclusion After an initial learning curve with regards to total cumulative doses, consistently high biologically effective doses have been employed translating into high local tumor control at 1 and 2 years. The true impact of histology and motion management method on treated metastases control deserve deeper analysis. Overall survival is mainly influenced by histology and metastatic tumor burden.}, language = {en} } @phdthesis{Zehner2024, author = {Zehner, Leonie Constanze}, title = {Evaluierung der Rezidivbestrahlung des Prostatakarzinoms}, doi = {10.25972/OPUS-35123}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-351230}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {Es erfolgte eine Evaluierung von Bestrahlungsdaten aus der Strahlentherapie der Universit{\"a}tsklinik W{\"u}rzburg von 435 Patienten mit biochemischen oder klinischen Rezidiv des Prostatakarzinoms. Der prim{\"a}re Endpunkt war das biochemisch rezidivfreie {\"U}berleben. Sekund{\"a}re Endpunkte waren das Auftreten von Fernmetastasen und das Versterben der Patienten. Zudem wurde der Einfluss patienten-, tumor-, und behandlungsspezifischer Faktoren {\"u}berpr{\"u}ft.}, subject = {Prostata}, language = {de} } @article{ShirakashiSisarioTabanetal.2023, author = {Shirakashi, Ryo and Sisario, Dmitri and Taban, Danush and Korsa, Tessa and Wanner, Sophia B. and Neubauer, Julia and Djuzenova, Cholpon S. and Zimmermann, Heiko and Sukhorukov, Vladimir L.}, title = {Contraction of the rigor actomyosin complex drives bulk hemoglobin expulsion from hemolyzing erythrocytes}, series = {Biomechanics and Modeling in Mechanobiology}, volume = {22}, journal = {Biomechanics and Modeling in Mechanobiology}, number = {2}, doi = {10.1007/s10237-022-01654-6}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325107}, pages = {417-432}, year = {2023}, abstract = {Erythrocyte ghost formation via hemolysis is a key event in the physiological clearance of senescent red blood cells (RBCs) in the spleen. The turnover rate of millions of RBCs per second necessitates a rapid efflux of hemoglobin (Hb) from RBCs by a not yet identified mechanism. Using high-speed video-microscopy of isolated RBCs, we show that electroporation-induced efflux of cytosolic ATP and other small solutes leads to transient cell shrinkage and echinocytosis, followed by osmotic swelling to the critical hemolytic volume. The onset of hemolysis coincided with a sudden self-propelled cell motion, accompanied by cell contraction and Hb-jet ejection. Our biomechanical model, which relates the Hb-jet-driven cell motion to the cytosolic pressure generation via elastic contraction of the RBC membrane, showed that the contributions of the bilayer and the bilayer-anchored spectrin cytoskeleton to the hemolytic cell motion are negligible. Consistent with the biomechanical analysis, our biochemical experiments, involving extracellular ATP and the myosin inhibitor blebbistatin, identify the low abundant non-muscle myosin 2A (NM2A) as the key contributor to the Hb-jet emission and fast hemolytic cell motion. Thus, our data reveal a rapid myosin-based mechanism of hemolysis, as opposed to a much slower diffusive Hb efflux.}, language = {en} } @article{GrabenbauerFlentje2022, author = {Grabenbauer, Felix and Flentje, Michael}, title = {Salvage-Bestrahlung der Prostataloge: Mitbestrahlung der regionalen LK und Bedeutung der ADT}, series = {Strahlentherapie und Onkologie}, volume = {198}, journal = {Strahlentherapie und Onkologie}, number = {12}, doi = {10.1007/s00066-022-02001-5}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325047}, pages = {1119-1121}, year = {2022}, abstract = {No abstract available.}, language = {de} } @article{KlementAbbasiSengerAdebahretal.2019, author = {Klement, Rainer J. and Abbasi-Senger, N. and Adebahr, S. and Alheid, H. and Allgaeuer, M. and Becker, G. and Blanck, O. and Boda-Heggemann, J. and Brunner, T. and Duma, M. and Eble, M. J. and Ernst, I. and Gerum, S. and Habermehl, D. and Hass, P. and Henkenberens, C. and Hildebrandt, G. and Imhoff, D. and Kahl, H. and Klass, N. D. and Krempien, R. and Lewitzki, V. and Lohaus, F. and Ostheimer, C. and Papachristofilou, A. and Petersen, C. and Rieber, J. and Schneider, T. and Schrade, E. and Semrau, R. and Wachter, S. and Wittig, A. and Guckenberger, M. and Andratschke, N.}, title = {The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases}, series = {BMC Cancer}, volume = {19}, journal = {BMC Cancer}, doi = {10.1186/s12885-019-5362-5}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325877}, year = {2019}, abstract = {Background The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer. Methods The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS. Results Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC. Conclusion In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.}, language = {en} } @article{TamihardjaLawrenzLutyjetal.2022, author = {Tamihardja, J{\"o}rg and Lawrenz, Ingulf and Lutyj, Paul and Weick, Stefan and Guckenberger, Matthias and Polat, B{\"u}lent and Flentje, Michael}, title = {Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer}, series = {Strahlentherapie und Onkologie}, volume = {198}, journal = {Strahlentherapie und Onkologie}, number = {8}, doi = {10.1007/s00066-022-01953-y}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325055}, pages = {735-743}, year = {2022}, abstract = {Purpose Dose-escalated external beam radiation therapy (EBRT) and EBRT + high-dose-rate brachytherapy (HDR-BT) boost are guideline-recommended treatment options for localized prostate cancer. The purpose of this study was to compare long-term outcome and toxicity of dose-escalated EBRT versus EBRT + HDR-BT boost. Methods From 2002 to 2019, 744 consecutive patients received either EBRT or EBRT + HDR-BT boost, of whom 516 patients were propensity score matched. Median follow-up was 95.3 months. Cone beam CT image-guided EBRT consisted of 33 fractions of intensity-modulated radiation therapy with simultaneous integrated boost up to 76.23 Gy (D\(_{Mean}\)). Combined treatment was delivered as 46 Gy (D\(_{Mean}\)) EBRT, followed by two fractions HDR-BT boost with 9 Gy (D\(_{90\\%}\)). Propensity score matching was applied before analysis of the primary endpoint, estimated 10-year biochemical relapse-free survival (bRFS), and the secondary endpoints metastasis-free survival (MFS) and overall survival (OS). Prognostic parameters were analyzed by Cox proportional hazard modelling. Genitourinary (GU)/gastrointestinal (GI) toxicity evaluation used the Common Toxicity Criteria for Adverse Events (v5.0). Results The estimated 10-year bRFS was 82.0\% vs. 76.4\% (p = 0.075) for EBRT alone versus combined treatment, respectively. The estimated 10-year MFS was 82.9\% vs. 87.0\% (p = 0.195) and the 10-year OS was 65.7\% vs. 68.9\% (p = 0.303), respectively. Cumulative 5‑year late GU ≥ grade 2 toxicities were seen in 23.6\% vs. 19.2\% (p = 0.086) and 5‑year late GI ≥ grade 2 toxicities in 11.1\% vs. 5.0\% of the patients (p = 0.002); cumulative 5‑year late grade 3 GU toxicity occurred in 4.2\% vs. 3.6\% (p = 0.401) and GI toxicity in 1.0\% vs. 0.3\% (p = 0.249), respectively. Conclusion Both treatment groups showed excellent long-term outcomes with low rates of severe toxicity.}, language = {en} } @article{KimpelSchindlerSchmidtPenningtonetal.2023, author = {Kimpel, Otilia and Schindler, Paul and Schmidt-Pennington, Laura and Altieri, Barbara and Megerle, Felix and Haak, Harm and Pittaway, James and Dischinger, Ulrich and Quinkler, Marcus and Mai, Knut and Kroiss, Matthias and Polat, B{\"u}lent and Fassnacht, Martin}, title = {Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma}, series = {British Journal of Cancer}, volume = {128}, journal = {British Journal of Cancer}, number = {4}, doi = {10.1038/s41416-022-02082-0}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324411}, pages = {586-593}, year = {2023}, abstract = {Background International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low. Methods We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses. Results In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50-60 Gy (n = 20) or 20-49 Gy (n = 69), stereotactic body RT of 35-50 Gy (SBRT) (n = 36), or brachytherapy of 12-25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0-148.6). In comparison to cRT\(_{20-49Gy}\), tTTP was significantly longer for cRT\(_{50-60Gy}\) (multivariate adjusted HR 0.10; 95\% CI 0.03-0.33; p < 0.001) and SBRT (HR 0.31; 95\% CI 0.12-0.80; p = 0.016), but not for BT (HR 0.66; 95\% CI 0.22-1.99; p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established. Conclusions This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.}, language = {en} } @article{HuflageKunzHendeletal.2023, author = {Huflage, Henner and Kunz, Andreas Steven and Hendel, Robin and Kraft, Johannes and Weick, Stefan and Razinskas, Gary and Sauer, Stephanie Tina and Pennig, Lenhard and Bley, Thorsten Alexander and Grunz, Jan-Peter}, title = {Obesity-related pitfalls of virtual versus true non-contrast imaging — an intraindividual comparison in 253 oncologic patients}, series = {Diagnostics}, volume = {13}, journal = {Diagnostics}, number = {9}, issn = {2075-4418}, doi = {10.3390/diagnostics13091558}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-313519}, year = {2023}, abstract = {Objectives: Dual-source dual-energy CT (DECT) facilitates reconstruction of virtual non-contrast images from contrast-enhanced scans within a limited field of view. This study evaluates the replacement of true non-contrast acquisition with virtual non-contrast reconstructions and investigates the limitations of dual-source DECT in obese patients. Materials and Methods: A total of 253 oncologic patients (153 women; age 64.5 ± 16.2 years; BMI 26.6 ± 5.1 kg/m\(^2\)) received both multi-phase single-energy CT (SECT) and DECT in sequential staging examinations with a third-generation dual-source scanner. Patients were allocated to one of three BMI clusters: non-obese: <25 kg/m\(^2\) (n = 110), pre-obese: 25-29.9 kg/m\(^2\) (n = 73), and obese: >30 kg/m\(^2\) (n = 70). Radiation dose and image quality were compared for each scan. DECT examinations were evaluated regarding liver coverage within the dual-energy field of view. Results: While arterial contrast phases in DECT were associated with a higher CTDI\(_{vol}\) than in SECT (11.1 vs. 8.1 mGy; p < 0.001), replacement of true with virtual non-contrast imaging resulted in a considerably lower overall dose-length product (312.6 vs. 475.3 mGy·cm; p < 0.001). The proportion of DLP variance predictable from patient BMI was substantial in DECT (R\(^2\) = 0.738) and SECT (R\(^2\) = 0.620); however, DLP of SECT showed a stronger increase in obese patients (p < 0.001). Incomplete coverage of the liver within the dual-energy field of view was most common in the obese subgroup (17.1\%) compared with non-obese (0\%) and pre-obese patients (4.1\%). Conclusion: DECT facilitates a 30.8\% dose reduction over SECT in abdominal oncologic staging examinations. Employing dual-source scanner architecture, the risk for incomplete liver coverage increases in obese patients.}, language = {en} } @phdthesis{Mann2024, author = {Mann, Daniel}, title = {Empowerment bei Krebspatient:innen}, doi = {10.25972/OPUS-34752}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-347524}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {Die Fragestellung, ob Question-Prompt-Lists (QPLs) interaktionales Empowerment f{\"o}rdern, wurde nach derzeitigem Kenntnisstand noch nicht untersucht. Bei QPLs handelt es sich um kurze Fragensets oder Kernfragen bez{\"u}glich der eigenen Erkrankung oder der Behandlung, die Patient:innen beispielsweise unmittelbar vor einem Aufkl{\"a}rungsgespr{\"a}ch erhalten, um sich aktiv auf dieses vorzubereiten. Der Nutzen einer solchen QPL konnte bereits in zahlreichen Studien belegt werden. Ebenso kommt der Thematik Empowerment bei der Behandlung von Krebspatient:innen eine wichtige Rolle zu: die Betroffenen sollen dahingehend ermutigt und best{\"a}rkt werden, sich aktiv mit der eigenen Erkrankung, deren Folgen und Behandlung auseinanderzusetzen, um so schließlich ein h{\"o}heres Maß an Kontrolle und Lebensqualit{\"a}t zu erlangen. Ziel der Studie war es, den positiven Effekt einer QPL bez{\"u}glich des Empowerments der Teilnehmer:innen aufzuzeigen. Die Fragestellung dieser prospektiv randomisiert kontrollierten Studie war es, ob eine QPL einen signifikanten Effekt auf das Empowerment von Krebspatient:innen haben kann. Die Datenerhebung erfolgte in der Ambulanz f{\"u}r Strahlentherapie des Universit{\"a}tsklinikums W{\"u}rzburgs. Insgesamt konnten 279 Patient:innen in die Studie eingeschlossen werden, 140 Teilnehmer:innen in der Interventionsgruppe und 139 Teilnehmer:innen in der Kontrollgruppe, die nach Randomisierung jeweils ihrer Gruppe zugeteilt wurden. Die Patient:innen der Interventionsgruppe erhielten unmittelbar vor dem Gespr{\"a}ch mit dem behandelnden Arzt/ der behandelnden {\"A}rztin eine QPL, anhand derer sie sich individuelle Fragen als Vorbereitung auf das Aufkl{\"a}rungsgespr{\"a}ch {\"u}berlegen konnten, wohingegen die Teilnehmer:innen der Kontrollgruppe keine solche QPL erhielten. Die aufkl{\"a}renden {\"A}rzte/ {\"A}rztinnen wussten jeweils nicht, welche Patient:innen zuvor eine QPL erhalten hatten. Nach dem Aufkl{\"a}rungsgespr{\"a}ch f{\"u}llten beide Gruppen von Teilnehmer:innen dann einen Fragebogen aus, mit Hilfe dessen nach Addition der einzelnen Fragewerte zu einem Summen-Score das Maß an Empowerment gemessen werden sollte. Hierbei konnte gezeigt werden, dass sich der Mittelwert des Summen-Scores signifikant zwischen der Interventionsgruppe (M=21,7; SE=0,22; SD=2,65) und der Kontrollgruppe (M=20,8; SE=0,26; SD=3,08) bei einem Signifikanzlevel von alpha=0,05 und einer Effektgr{\"o}ße von d=0,29 (r=0,16): t(277)=2,71; p=0,007, 95\% CI [-1,61, -0,26] unterschied. Außerdem konnte beim Vergleich der einzelnen Fragen des Auswertungsbogens selbst bei 4 von 8 Frageitems ein signifikanter Unterschied zwischen Interventionsgruppe und Kontrollgruppe gezeigt werden. Hierbei handelte es sich um Fragen, die den Fokus auf die relationale, also die beziehungsorientierte Komponente des Aufkl{\"a}rungsgespr{\"a}chs legten, im Gegensatz zu den Fragen, die den Fokus auf den reinen Zuwachs von Informationen, also die informative Komponente des Aufkl{\"a}rungsgespr{\"a}chs legten. Somit kann abschließend von einem signifikanten Effekt der Intervention, dem Gebrauch einer QPL, in Bezug auf das Konstrukt Empowerment bei Krebspatient:innen ausgegangen werden. Mit der QPL konnte ein einfaches, gut durchf{\"u}hrbares Instrument in den klinischen Alltag der Strahlenambulanz des Universit{\"a}tsklinikums W{\"u}rzburg implementiert werden, das von einem Großteil der Patient:innen gut angenommen und als hilfreich bewertet wurde.  }, subject = {Krebskranker}, language = {de} } @article{BroschKorsaTabanetal.2022, author = {Brosch, Philippa K. and Korsa, Tessa and Taban, Danush and Eiring, Patrick and Hildebrand, Sascha and Neubauer, Julia and Zimmermann, Heiko and Sauer, Markus and Shirakashi, Ryo and Djuzenova, Cholpon S. and Sisario, Dmitri and Sukhorukov, Vladimir L.}, title = {Glucose and inositol transporters, SLC5A1 and SLC5A3, in glioblastoma cell migration}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {23}, issn = {2072-6694}, doi = {10.3390/cancers14235794}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297498}, year = {2022}, abstract = {(1) Background: The recurrence of glioblastoma multiforme (GBM) is mainly due to invasion of the surrounding brain tissue, where organic solutes, including glucose and inositol, are abundant. Invasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC). Here, we explore the role of glucose (SLC5A1) and inositol transporters (SLC5A3) in GBM cell migration. (2) Methods: Using immunofluorescence microscopy, we visualized the subcellular localization of SLC5A1 and SLC5A3 in two highly motile human GBM cell lines. We also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol. (3) Results: While GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition. In the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge. In single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium. Interestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively. (4) Conclusion: We provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome. Our findings suggest that SLC inhibition is a promising approach to GBM treatment.}, language = {en} } @article{DiefenhardtMartinLudmiretal.2022, author = {Diefenhardt, Markus and Martin, Daniel and Ludmir, Ethan B. and Fleischmann, Maximilian and Hofheinz, Ralf-Dieter and Ghadimi, Michael and Kosmala, Rebekka and Polat, B{\"u}lent and Friede, Tim and Minsky, Bruce D. and R{\"o}del, Claus and Fokas, Emmanouil}, title = {Development and validation of a predictive model for toxicity of neoadjuvant chemoradiotherapy in rectal cancer in the CAO/ARO/AIO-04 phase III trial}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {18}, issn = {2072-6694}, doi = {10.3390/cancers14184425}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-288081}, year = {2022}, abstract = {Background: There is a lack of predictive models to identify patients at risk of high neoadjuvant chemoradiotherapy (CRT)-related acute toxicity in rectal cancer. Patient and Methods: The CAO/ARO/AIO-04 trial was divided into a development (n = 831) and a validation (n = 405) cohort. Using a best subset selection approach, predictive models for grade 3-4 acute toxicity were calculated including clinicopathologic characteristics, pretreatment blood parameters, and baseline results of quality-of-life questionnaires and evaluated using the area under the ROC curve. The final model was internally and externally validated. Results: In the development cohort, 155 patients developed grade 3-4 toxicities due to CRT. In the final evaluation, 15 parameters were included in the logistic regression models using best-subset selection. BMI, gender, and emotional functioning remained significant for predicting toxicity, with a discrimination ability adjusted for overfitting of AUC 0.687. The odds of experiencing high-grade toxicity were 3.8 times higher in the intermediate and 6.4 times higher in the high-risk group (p < 0.001). Rates of toxicity (p = 0.001) and low treatment adherence (p = 0.007) remained significantly different in the validation cohort, whereas discrimination ability was not significantly worse (DeLong test 0.09). Conclusion: We developed and validated a predictive model for toxicity using gender, BMI, and emotional functioning. Such a model could help identify patients at risk for treatment-related high-grade toxicity to assist in treatment guidance and patient participation in shared decision making.}, language = {en} } @phdthesis{Warm2023, author = {Warm, Tobias Dominik}, title = {Einstellung von Pflegeheimbewohnenden zur vorausschauenden Versorgungsplanung}, doi = {10.25972/OPUS-32373}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-323739}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2023}, abstract = {Hintergrund: Aufgrund des demographischen Wandels nimmt der Anteil der Pflegebed{\"u}rftigen in Deutschland zu. Aktuelle Erhebungen zeigen, dass der Einzug in station{\"a}re Pflegeeinrichtungen erst in h{\"o}herem Lebensalter und bei steigenden Komorbidit{\"a}ten erfolgt, womit ein erh{\"o}hter Bedarf an medizinischer und pflegerischer Versorgung einhergeht. Ziele der Studie: Durch die Befragung der Pflegeheimbewohnenden sollten Erkenntnisse {\"u}ber eine bereits erfolgte Vorsorgedokumentation und deren Versorgungsw{\"u}nsche am Lebensende gewonnen werden. Methodik: Es wurde eine multizentrische, explorative Beobachtungsstudie als Vollerhebung in elf bayerischen Pflegeeinrichtungen durchgef{\"u}hrt. Die Datenerhebung erfolgte vor Ort durch den Promovierenden mittels eines standardisierten Fragebogens im Zeitraum von April 2018 bis Mai 2019. Im Zuge der statistischen Auswertung wurden deskriptive Statistiken erstellt, Gruppenunterschiede wurden zweiseitig mittels Fisher-Exakt-Test auf Unabh{\"a}ngigkeit hin {\"u}berpr{\"u}ft und paarweise Gruppenvergleiche durch bin{\"a}re logistische Regression durchgef{\"u}hrt. Ergebnisse: Von 1207 wurden 269 (22,3 \%) Pflegeheimbewohnende in die Studie eingeschlossen. Von den Studienteilnehmenden hatten sich 55 \% bereits intensiver mit dem eigenen Sterben auseinandergesetzt. 50,9 \% der Pflegeheimbewohnenden w{\"u}nschten im Falle einer zum Tode f{\"u}hrenden Erkrankung eine alleinige pflegerische und medizinische Versorgung in der Einrichtung. 19,7 \% w{\"u}nschten in diesem Fall eine Klinikeinweisung, aber den Verzicht auf Anwendung invasiver Therapiemaßnahmen. Ein Wunschsterbeort lag bei 65,4 \% der Pflegeheimbewohnenden vor. Von diesen w{\"u}nschten 76,7 \% in der Pflegeeinrichtung zu versterben. 71,7 \% der Pflegeheimbewohnenden w{\"u}nschten, nicht allein zu versterben. {\"U}ber ihre Versorgungsw{\"u}nsche hatten bereits 45,7 \% aller Studienteilnehmenden eine andere Person, mehrheitlich die eigenen Angeh{\"o}rigen, informiert. 49,1 \% der Pflegeheimbewohnenden w{\"u}nschten sich eine Erfassung der Versorgungsw{\"u}nsche direkt bei Einzug in die Einrichtung. In 63,6 \% der F{\"a}lle lag mindestens ein schriftliches Vorsorgedokument vor. Eine Patientenverf{\"u}gung hatten 45,5 \%, eine Vorsorgevollmacht 46,5 \% der Pflegeheimbewohnenden verfasst. Schlussfolgerungen: Pflegeheimbewohnende haben mehrheitlich konkrete Vorstellungen f{\"u}r ihre Versorgung am Lebensende. Die vorhandenen Versorgungsw{\"u}nsche sollten auf Wunsch der Pflegeheimbewohnenden erfasst werden, um eine entsprechende Versorgung auch im Falle einer eintretenden Einwilligungsunf{\"a}higkeit zu erm{\"o}glichen. Der Zeitpunkt der Erfassung der Versorgungsw{\"u}nsche sollte im Hinblick auf das steigende Lebensalter bei Einzug in deutsche Pflegeeinrichtungen und auf die altersbedingt steigende Rate an kognitiven Einschr{\"a}nkungen m{\"o}glichst fr{\"u}hzeitig gew{\"a}hlt werden. Hierbei stellen Konzepte der vorausschauenden Versorgungsplanung eine M{\"o}glichkeit dar, um einen Dialog zwischen den beteiligten Akteuren zu erm{\"o}glichen.}, subject = {Versorgungsplanung}, language = {de} } @phdthesis{Maier2023, author = {Maier, Marco}, title = {Therapiezieleinsch{\"a}tzung von palliativ bestrahlten Patienten bei Erstvorstellung in der Radioonkologie}, doi = {10.25972/OPUS-32111}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-321119}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2023}, abstract = {In der vorliegenden Arbeit wurden die H{\"a}ufigkeit und m{\"o}gliche Pr{\"a}diktoren f{\"u}r eine {\"u}beroptimistische Therapiezieleinsch{\"a}tzung von palliativ bestrahlten onkologischen Patienten der Klinik und Poliklinik f{\"u}r Strahlentherapie des Universit{\"a}tsklinikum W{\"u}rzburg untersucht. Dazu wurden die Frage zur Therapiezieleinsch{\"a}tzung, die Integrated Palliative Care Outcome Scale (IPOS), das Distress-Thermometer und das Fatigue-Screening aus dem Patientenselbsteinsch{\"a}tzungsbogen, den die Patienten routinem{\"a}ßig vor dem {\"a}rztlichen Erstgespr{\"a}ch erhalten, sowie soziodemographische und krankheitsbezogene Daten aus der elektronischen Patientenakte analysiert (Untersuchungszeitraum 05/2018-05/2019). Die Einsch{\"a}tzung des Therapieziels galt als {\"u}beroptimistisch, wenn ein Patient f{\"a}lschlicherweise von dem Behandlungsziel „Heilung" ausging. Von einer realistischen Therapiezieleinsch{\"a}tzung wurde ausgegangen, wenn ein Patient von der Nichtheilbarkeit seiner Krebserkrankung ausging. Insgesamt wurden Daten von 283 Patienten ausgewertet, davon 133 Frauen (47\%) und 150 M{\"a}nner (53\%). Das mittlere Alter lag bei 66,7 Jahren (Spannweite 30-95 Jahre). Die drei h{\"a}ufigsten Tumorentit{\"a}ten waren Lungen- (26,9\%), Brust- (18,0\%) und Prostatakrebs (10,2\%). 64,7\% (183/283) der Patienten dieser Studie sch{\"a}tzten ihr Therapieziel {\"u}beroptimistisch ein. Es fanden sich statistisch signifikante Zusammenh{\"a}nge (p<0,05) mit einzelnen IPOS-Items, der bisherigen Dauer der Therapie unter palliativer Intention und dem Karnofsky-Index . Die beiden Variablen „Dauer der Therapie unter palliativer Intention" und „Karnofsky-Index" wurden in einer bin{\"a}r logistischen Regression als Pr{\"a}diktoren f{\"u}r eine {\"u}beroptimistische Therapiezieleinsch{\"a}tzung identifiziert. Da die Selbsteinsch{\"a}tzung vor der Erstbegegnung mit dem Strahlentherapeuten erfolgte, bleibt offen, inwieweit die Patienten- und Arzteinsch{\"a}tzung nach dem Aufkl{\"a}rungsgespr{\"a}ch h{\"a}ufiger {\"u}bereinstimmen als in der vorliegenden Studie (35,3\% realistische Therapiezieleinsch{\"a}tzung).}, subject = {Palliativmedizin}, language = {de} } @phdthesis{Hartmannsgruber2023, author = {Hartmannsgruber, Johann}, title = {Erfassung und Nutzen von Frailty in der Routine der Radioonkologie}, doi = {10.25972/OPUS-31929}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319298}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2023}, abstract = {Im Rahmen dieser Arbeit wurde ein Frailty-Screening mittels Clinical Frailty Scale (CFS) bei 246 Patienten im Alter ≥70 Jahren in die klinische Routine der Klinik und Poliklinik f{\"u}r Strahlentherapie des Universit{\"a}tsklinikums W{\"u}rzburg eingef{\"u}hrt. Die prospektive Erhebung der CFS erfolgte nach entsprechender Schulung innerhalb eines Zeitraums von 6 Monaten im Rahmen des Erstgespr{\"a}ches vor fraktioniert perkutaner Radiatio. In einem sekund{\"a}ren Projektabschnitt wurden innerhalb eines Nachbeobachtungszeitraumes von insgesamt 365 Tagen nach Bestrahlungsbeginn Komplikationen retrospektiv erfasst. Nach entsprechender Mitarbeiterschulung wurde eine erfolgreiche Implementierung des Frailty-Screenings in die klinische Routine erzielt. In der schließenden statistischen Auswertung zeigte sich ein h{\"o}heres Ausmaß an Frailty pr{\"a}diktiv f{\"u}r einen komplikationsreichen Therapieverlauf. Dabei wurden akute Toxizit{\"a}t, Therapieabbr{\"u}che, station{\"a}re Notaufnahmen, sowie ein Versterben analysiert. Abschließend wurde analysiert, ob sich innerhalb des ECOG Performance Status Subgruppen mittels Frailty identifizieren ließen. Dabei wurde ein besonderes Augenmerk auf das Vorliegen gebrechlicher Patienten innerhalb der Patientengruppen mit verh{\"a}ltnism{\"a}ßig guter Funktion (ECOG 0 bzw. 1) gelegt. In Zusammenschau der Befunde des PS (ECOG) und CFS zeigten sich innerhalb der ECOG Grad 0 und Grad 1 eine heterogene Aufteilung „fitter" bis „gebrechlicher" Patienten. Die Ergebnisse dieser Arbeit zeigen, dass ein Frailty-Screening mittels CFS nach entsprechender Schulung im radioonkologischen Alltag umsetzbar ist und in ein Gesamtkonzept eingebettet werden sollte. Aufgrund des pr{\"a}diktiven Wertes in Bezug auf ein negatives Outcome und dem Vorliegen von Gebrechlichkeit auch bei Patienten mit verh{\"a}ltnism{\"a}ßig gutem PS (ECOG 0, 1), k{\"o}nnten {\"a}ltere Patienten von einem zus{\"a}tzlichen Frailty-Screening profitieren, dies insbesondere im Hinblick auf die zunehmende Inanspruchnahme radioonkologischer Therapien.}, subject = {Frailty}, language = {de} } @phdthesis{Alban2023, author = {Alban, Eva Nicole}, title = {Ergebnisse der intraoperativen Boost-Bestrahlung (IORT) des Tumorbettes gefolgt von perkutaner Ganzbrustbestrahlung (WBRT) bei Mammakarzinompatientinnen}, doi = {10.25972/OPUS-31788}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-317888}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2023}, abstract = {In dieser Arbeit wird die intraoperative Boost-Bestrahlung mit 9 oder 20 Gy bei Mammakarzinompatientinnen evaluiert. Es werden das onkologische Ergebnis, die bestrahlungsassoziierte Toxizit{\"a}t, das kosmetische Therapieergebnis und die Lebensqualit{\"a}t ausgewertet. Die Analyse bezieht sich auf 124 F{\"a}lle im fr{\"u}hen Brustkrebsstadium.}, subject = {Intraoperative Strahlentherapie}, language = {de} } @article{ZimmermannRichterWeicketal.2022, author = {Zimmermann, Marcus and Richter, Anne and Weick, Stefan and Exner, Florian and Mantel, Frederick and Diefenhardt, Markus and Fokas, Emmanouil and Kosmala, Rebekka and Flentje, Michael and Polat, B{\"u}lent}, title = {Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center}, series = {Scientific Reports}, volume = {12}, journal = {Scientific Reports}, doi = {10.1038/s41598-022-25647-8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-301255}, year = {2022}, abstract = {In locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is regarded as standard treatment. We assessed acute toxicities in patients receiving conventional 3D-conformal radiotherapy (3D-RT) and correlated them with dosimetric parameters after re-planning with volumetric modulated arc therapy (VMAT). Patients were randomized within the multicenter CAO/ARO/AIO-12 trial and received 50.4 Gy in 28 fractions and simultaneous chemotherapy with fluorouracil and oxaliplatin. Organs at risk (OAR) were contoured in a standardized approach. Acute toxicities and dose volume histogram parameters of 3D-RT plans were compared to retrospectively calculated VMAT plans. From 08/2015 to 01/2018, 35 patients with LARC were treated at one study center. Thirty-four patients were analyzed of whom 1 (3\%) was UICC stage II and 33 (97\%) patients were UICC stage III. Grade 3 acute toxicities occurred in 5 patients (15\%). Patients with acute grade 1 cystitis (n = 9) had significantly higher D\(_{mean}\) values for bladder (29.4 Gy vs. 25.2 Gy, p < 0.01) compared to patients without bladder toxicities. Acute diarrhea was associated with small bowel volume (grade 2: 870.1 ccm vs. grade 0-1: 647.3 ccm; p < 0.01) and with the irradiated volumes V5 to V50. Using VMAT planning, we could reduce mean doses and irradiated volumes for all OAR: D\(_{mean}\) bladder (21.9 Gy vs. 26.3 Gy, p < 0.01), small bowel volumes V5-V45 (p < 0.01), D\(_{mean}\) anal sphincter (34.6 Gy vs. 35.6 Gy, p < 0.01) and D\(_{mean}\) femoral heads (right 11.4 Gy vs. 25.9 Gy, left 12.5 Gy vs. 26.6 Gy, p < 0.01). Acute small bowel and bladder toxicities were dose and volume dependent. Dose and volume sparing for all OAR could be achieved through VMAT planning and might result in less acute toxicities.}, language = {en} } @article{LisowskiTroemelLutyjetal.2022, author = {Lisowski, Dominik and Tr{\"o}mel, Jannik and Lutyj, Paul and Lewitzki, Victor and Hartrampf, Philipp E. and Polat, B{\"u}lent and Flentje, Michael and Tamihardja, J{\"o}rg}, title = {Health-related quality of life and clinical outcome after radiotherapy of patients with intracranial meningioma}, series = {Scientific Reports}, volume = {12}, journal = {Scientific Reports}, doi = {10.1038/s41598-022-24192-8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-301233}, year = {2022}, abstract = {This retrospective, single-institutional study investigated long-term outcome, toxicity and health-related quality of life (HRQoL) in meningioma patients after radiotherapy. We analyzed the data of 119 patients who received radiotherapy at our department from 1997 to 2014 for intracranial WHO grade I-III meningioma. Fractionated stereotactic radiotherapy (FSRT), intensity modulated radiotherapy (IMRT) or radiosurgery radiation was applied. The EORTC QLQ-C30 and QLQ-BN20 questionnaires were completed for assessment of HRQoL. Overall survival (OS) for the entire study group was 89.6\% at 5 years and 75.9\% at 10 years. Local control (LC) at 5 and 10 years was 82.4\% and 73.4\%, respectively. Local recurrence was observed in 22 patients (18.5\%). Higher grade acute and chronic toxicities were observed in seven patients (5.9\%) and five patients (4.2\%), respectively. Global health status was rated with a mean of 59.9 points (SD 22.3) on QLQ-C30. In conclusion, radiotherapy resulted in very good long-term survival and tumor control rates with low rates of severe toxicities but with a deterioration of long-term HRQoL.}, language = {en} }